Our Team
A Biotechnology Company is Ultimately a bet on the Team.
We have carefully assembled a team of leading scientists, each bringing an average of 25+ years of experience in drug development. Their expertise spans neuroscience, receptor pharmacology, and precision therapeutics—particularly in the modulation of neurological pathways relevant to epilepsy.
With deep knowledge of receptor-targeted therapies and brain signaling, our team is dedicated to pioneering innovative treatments for drug-resistant seizures and transforming the landscape of epilepsy care.
Director, Chief Science Officer,
Jan Torleif Pedersen
Jan Torleif Pedersen
Director, Chief Science Officer
Scientific Advisory Board
Epilepsy specialists
Michael P. Bogenschutz, MD
Director
Robert C. Malenka, MD, PhD
Director
Herbert Y. Meltzer
Director
Dr. Peter Hendricks Ph.D
Senior Advisor
Leadership
Ian McDonald
Chief Executive Officer, Director
Ryan Cheung
Chief Financial Officer
Jianmin Duan Ph.D
Vice President of Pharmacology
Alex Vasilkevich
Chief Operating Officer, Senior Scientific Officer
Dr. John McCorvy Ph.D
Senior Advisor
John McCall, Ph.D
Senior Advisor
Mark A. Geyer, PhD
Advisor
Krista Lanctot PhD
Advisor
Lew Truex
Toxicology Advisor
Dr. Narayan R. Kissoon MD
Senior Advisor
Dr. Peter R. Kowey, MD
Advisor
Dr. Guilio Vistoli Ph.D
Senior Advisor
Board of Directors
Jeremy Fryzuk
Director
Nils Bottler
Director
Ian McDonald
Chief Executive Officer, Director
Jan Torleif Pedersen
Director, Chief Science Officer
David Weiner
Non-Executive Director
